HDFC Securities includes ITC in broad post-Q1FY27 coverage review
HDFC Securities has issued post-Q1FY27 reviews across ITC and a range of Indian companies, including Sun Pharma, Maruti Suzuki, Bajaj Finserv and Kajaria Ceramics. The available report excerpt does not specify ITC’s rating, target price or investment rationale.
What happened
HDFC Securities issued post-Q1FY27 reviews covering ITC and other Indian companies. The brokerage maintained constructive calls across several stocks and
Key facts
- Rs 2,320
- Rs 7,094
- Rs 5,325
Why this matters
The coverage mention reinforces ITC’s relevance among major Indian consumer businesses, but provides no disclosed catalyst or valuation signal for strategic decision-making.
What to watch
- Disclosure of HDFC Securities’ ITC rating, target price, valuation methodology and upside/downside rationale.
- Q1FY27 segment-level performance in cigarettes, FMCG-others, hotels, paperboards and agri-business.
- Changes in cigarette taxation or regulatory policy, including any GST-related developments.
- FMCG gross-margin movement, competitive promotional spending and contribution from newer brands.
- Consensus EPS revisions, foreign institutional flows and relative performance versus Indian consumer-staples peers.
- Await publication or circulation of ITC-specific rating, target price and earnings-estimate revisions from the full HDFC Securities note.
- Compare the brokerage’s assumptions for cigarette volume/pricing, FMCG revenue growth and EBITDA margin with management guidance and consensus.
- Track whether other brokerages revise ITC estimates after Q1FY27, which would indicate a broader earnings-expectation shift rather than isolated research coverage.
- Watch for commentary on capital allocation, hotel demerger-related value unlocking and the pace of FMCG profitability improvement.